AB-CHMINACA is an indazole-based synthetic cannabinoid (CB) that is structurally related to AB-FUBINACA , a high affinity ligand of the central CB1 receptor (Ki = 0.9 nM), by having a cyclohexyl group substituted for the 4-fluorophenyl group.[1][2] MDMB-CHMINACA is structurally related to AB-CHMINACA by bearing a similar cyclohexyl group; however, the terminal aminocarbonyl moiety is replaced by a methyl ester group and the isobutyl moiety is substituted with a tert-butyl group.[2] The physiological and toxicological properties of this compound have not been determined. This product is intended for research and forensic applications.
Reference:
[1]. Uchiyama, N., Matsuda, S., Wakana, D., et al. New cannabimimetic indazole derivatives, N-(1-amino-3methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB-PINACA) and N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA) identified as designer drugs in illegal products. Forensic Toxicol. 31(1), 93-100 (2013).
[2]. Buchler, I.P., Hayes, M.J., Hedge, S.G., et al. Indazole derivatives. 1-283 (2009).